𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Sarcoglycans in muscular dystrophy

✍ Scribed by Hack, Andrew A.; Groh, Margaret E.; McNally, Elizabeth M.


Publisher
John Wiley and Sons
Year
2000
Tongue
English
Weight
291 KB
Volume
48
Category
Article
ISSN
1059-910X

No coin nor oath required. For personal study only.

✦ Synopsis


Muscular dystrophy is a heterogeneous genetic disease that affects skeletal and cardiac muscle. The genetic defects associated with muscular dystrophy include mutations in dystrophin and its associated glycoproteins, the sarcoglycans. Furthermore, defects in dystrophin have been shown to cause a disruption of the normal expression and localization of the sarcoglycan complex. Thus, abnormalities of sarcoglycan are a common molecular feature in a number of dystrophies. By combining biochemistry, molecular cell biology, and human and mouse genetics, a growing understanding of the sarcoglycan complex is emerging. Sarcoglycan appears to be an important, independent mediator of dystrophic pathology in both skeletal muscle and heart. The absence of sarcoglycan leads to alterations of membrane permeability and apoptosis, two shared features of a number of dystrophies. ␀-sarcoglycan and ␦-sarcoglycan may form the core of the sarcoglycan subcomplex with ␣and β₯-sarcoglycan less tightly associated to this core. The relationship of β‘€-sarcoglycan to the dystrophin-glycoprotein complex remains unclear. Animals lacking ␣-, β₯and ␦-sarcoglycan have been described and provide excellent opportunities for further investigation of the function of sarcoglycan. Dystrophin with dystroglycan and laminin may be a mechanical link between the actin cytoskeleton and the extracellular matrix. By positioning itself in close proximity to dystrophin and dystroglycan, sarcoglycan may function to couple mechanical and chemical signals in striated muscle. Sarcoglycan may be an independent signaling or regulatory module whose position in the membrane is determined by dystrophin but whose function is carried out independent of the dystrophin-dystroglycan-laminin axis. Microsc.


πŸ“œ SIMILAR VOLUMES


Heart involvement in muscular dystrophie
✍ P. Melacini; M. Fanin; D.J. Duggan; M.P. Freda; A. Berardinelli; G.A. Danieli; A πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 320 KB

Mutations in the sarcoglycan genes cause autosomalrecessive muscular dystrophies. Because sarcoglycan genes and their protein products are highly expressed both in skeletal and cardiac muscle, patients with these mutations might be expected to be at risk to develop dilated cardiomyopathy. We therefo

Urinary dysfunction in Duchenne muscular
✍ James B. Caress; Milind J. Kothari; Stuart B. Bauer; Jeremy M. Shefner πŸ“‚ Article πŸ“… 1996 πŸ› John Wiley and Sons 🌐 English βš– 417 KB πŸ‘ 2 views

In Duchenne muscular dystrophy (DMD), sphincter muscles tend to be clinically spared. However, urinary incontinence is occasionally reported, usually late in the course of the disease. We wished to determine the etiology of urinary dysfunction in patients with DMD. Seven boys with DMD and urinary dy

Genetic heterogeneity in Duchenne muscul
✍ Zatz, Mayana ;Rabbi-Bortolini, Eliete ;Opitz, John M. πŸ“‚ Article πŸ“… 1987 πŸ› John Wiley and Sons 🌐 English βš– 76 KB πŸ‘ 2 views

We agree with Professor Emery that evidence is adding up suggesting heterogeneity of DMD at the molecular and cytogenetic levels Poyd and Buckle, 19861. However, this does not seem evident on clinical grounds. Our group of patients classified as mentally retarded [Bortolini and Zatz, 19861 all had

Maternal age in Duchenne muscular dystro
✍ Winter, R. M. ;Pembrey, M. E. ;Yasuda, Norikuzu πŸ“‚ Article πŸ“… 1983 πŸ› John Wiley and Sons 🌐 English βš– 142 KB πŸ‘ 2 views